CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 164 filers reported holding CLOVIS ONCOLOGY INC in Q4 2020. The put-call ratio across all filers is 1.33 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $37,000 | -65.7% | 18,424 | -53.6% | 0.00% | – |
| Q4 2021 | $108,000 | +21.3% | 39,686 | +98.1% | 0.00% | -100.0% |
| Q3 2021 | $89,000 | -18.3% | 20,036 | +6.5% | 0.00% | 0.0% |
| Q2 2021 | $109,000 | +31.3% | 18,811 | +59.4% | 0.00% | -66.7% |
| Q1 2021 | $83,000 | +33.9% | 11,802 | -9.0% | 0.00% | +50.0% |
| Q4 2020 | $62,000 | -17.3% | 12,976 | +0.4% | 0.00% | -33.3% |
| Q3 2020 | $75,000 | -3.8% | 12,918 | +12.1% | 0.00% | -25.0% |
| Q2 2020 | $78,000 | -76.4% | 11,522 | +58.2% | 0.00% | -50.0% |
| Q2 2018 | $331,000 | +6.8% | 7,283 | +23.9% | 0.01% | 0.0% |
| Q1 2018 | $310,000 | -23.8% | 5,877 | -1.7% | 0.01% | -27.3% |
| Q4 2017 | $407,000 | -11.5% | 5,981 | +7.1% | 0.01% | -21.4% |
| Q3 2017 | $460,000 | +2.2% | 5,587 | +16.1% | 0.01% | -6.7% |
| Q2 2017 | $450,000 | +62.5% | 4,811 | +10.4% | 0.02% | +7.1% |
| Q1 2017 | $277,000 | +3.4% | 4,357 | +49.5% | 0.01% | -50.0% |
| Q3 2015 | $268,000 | +18.6% | 2,915 | +13.3% | 0.03% | +27.3% |
| Q2 2015 | $226,000 | – | 2,573 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,997,826 | $10,834,000 | 0.69% |
| Ikarian Capital, LLC | 1,112,669 | $3,016,000 | 0.45% |
| Versant Venture Management, LLC | 101,855 | $276,000 | 0.15% |
| Virtus ETF Advisers LLC | 60,836 | $165,000 | 0.06% |
| EMFO, LLC | 21,500 | $58,000 | 0.05% |
| QVT Financial LP | 505,000 | $1,369,000 | 0.05% |
| QVT Financial LP | 505,000 | $1,369,000 | 0.05% |
| PINNACLE ASSOCIATES LTD | 706,336 | $1,914,000 | 0.03% |
| XTX Topco Ltd | 20,920 | $57,000 | 0.03% |
| State of Wyoming | 25,419 | $69,000 | 0.03% |